Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab
- 25 September 2023
- journal article
- letter
- Published by Wiley in Haemophilia
- Vol. 29 (6) , 1661-1664
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- How to assess parallelism in factor assays: coefficient of variation of results with different dilutions or slope ratio?International Journal of Laboratory Hematology, 2022
- Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapyHaemophilia, 2022
- Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation studyResearch and Practice in Thrombosis and Haemostasis, 2022
- Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving EmicizumabInternational Journal of Laboratory Hematology, 2020
- Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals)European Journal of Haematology, 2020
- Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)Haemophilia, 2019
- Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation AssaysThrombosis and Haemostasis, 2019
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- A Chromogenic Assay Allows Reliable Measurement of Factor VIII Levels in the Presence of Strong Lupus AnticoagulantsThrombosis and Haemostasis, 1998
- Anti-factor VIII Inhibitors and Lupus Anticoagulants in Haemophilia A PatientsThrombosis and Haemostasis, 1997